Structure Therapeutics is trading at $55.72, +4.86%, after announcing Phase 3 ACCOMPLISH dosing for aleniglipron in obesity trials.

  • Up to 4,700 patients are planned across two studies; John Berrios, formerly of Novo Nordisk, was appointed chief commercial officer.
  • The August 6 earnings update reported $1.3 billion in cash and projected funding through 2028.
  • No new August 10 announcement was identified; the move likely reflects continued reaction to these updates.